Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with concurrent chemoradiation followed by pembrolizumab with or without olaparib versus chemoradiation alone in newly diagnosed limited-stage small cell lung cancer
jRCT2031200296Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in small cell lung cancer (SCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031200296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200296.